Advicenne SA

Advicenne S.A. is a pharmaceutical company dedicated to developing medications for rare kidney disorders. The firm's primary experimental therapeutic, ADV7103, is currently undergoing development for treating distal renal tubular acidosis in both children and adults. Furthermore, ADV7103 is also being investigated for managing cystinuria, a genetic condition that affects kidney tubules. Additionally, Advicenne offers ADV6209, an oral liquid solution formulated for pediatric use, which aims to reduce anxiety and improve a child's ability to remain still. Established in 2007, Advicenne S.A. operates from its headquarters in Paris, France.